VIVA BIOTECH (01873) has disclosed its financial results for the year ended December 31, 2025. The group reported annual revenue of 1.729 billion yuan, representing a decrease of 12.9% compared to the previous year. Despite the decline in revenue, net profit reached 269 million yuan, an increase of 21.31% year-on-year. Basic earnings per share were reported at 0.1 yuan.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments